ATE245985T1 - Verbesserung der opioid-toleranz durch hemmung der induzierbaren stickstoffoxid-synthase zur behandlung von schmerzen - Google Patents

Verbesserung der opioid-toleranz durch hemmung der induzierbaren stickstoffoxid-synthase zur behandlung von schmerzen

Info

Publication number
ATE245985T1
ATE245985T1 AT98901665T AT98901665T ATE245985T1 AT E245985 T1 ATE245985 T1 AT E245985T1 AT 98901665 T AT98901665 T AT 98901665T AT 98901665 T AT98901665 T AT 98901665T AT E245985 T1 ATE245985 T1 AT E245985T1
Authority
AT
Austria
Prior art keywords
nitrogen oxide
oxide synthase
treat pain
opioid tolerance
inhibiting inducible
Prior art date
Application number
AT98901665T
Other languages
English (en)
Inventor
Daniela Salvemini
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE245985T1 publication Critical patent/ATE245985T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Materials For Medical Uses (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Processing Of Meat And Fish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98901665T 1997-01-09 1998-01-06 Verbesserung der opioid-toleranz durch hemmung der induzierbaren stickstoffoxid-synthase zur behandlung von schmerzen ATE245985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78181497A 1997-01-09 1997-01-09
PCT/US1998/000006 WO1998030220A1 (en) 1997-01-09 1998-01-06 Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain

Publications (1)

Publication Number Publication Date
ATE245985T1 true ATE245985T1 (de) 2003-08-15

Family

ID=25124020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98901665T ATE245985T1 (de) 1997-01-09 1998-01-06 Verbesserung der opioid-toleranz durch hemmung der induzierbaren stickstoffoxid-synthase zur behandlung von schmerzen

Country Status (10)

Country Link
EP (1) EP0966286B1 (de)
JP (1) JP2001508444A (de)
AT (1) ATE245985T1 (de)
AU (1) AU5813098A (de)
CA (1) CA2272941A1 (de)
DE (1) DE69816790T2 (de)
DK (1) DK0966286T3 (de)
ES (1) ES2205441T3 (de)
PT (1) PT966286E (de)
WO (1) WO1998030220A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
JPH09504524A (ja) * 1993-10-21 1997-05-06 ジー.ディー.サール アンド カンパニー 酸化窒素シンターゼ阻害剤として有用なアミジノ誘導体
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
ATE195933T1 (de) * 1994-03-10 2000-09-15 Searle & Co L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
DE4442116A1 (de) * 1994-11-25 1996-05-30 Cassella Ag 2-Amino-1,3-thiazine als Hemmstoffe der Stickstoffmonoxid-Synthase
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
GB9425701D0 (en) * 1994-12-20 1995-02-22 Wellcome Found Enzyme inhibitors
AU712995B2 (en) * 1995-05-10 1999-11-18 G.D. Searle & Co. Nitric oxide synthase inhibitors derived from cyclic amidines

Also Published As

Publication number Publication date
JP2001508444A (ja) 2001-06-26
DE69816790T2 (de) 2004-04-22
EP0966286B1 (de) 2003-07-30
DE69816790D1 (de) 2003-09-04
WO1998030220A1 (en) 1998-07-16
DK0966286T3 (da) 2003-11-17
ES2205441T3 (es) 2004-05-01
EP0966286A1 (de) 1999-12-29
PT966286E (pt) 2003-12-31
AU5813098A (en) 1998-08-03
CA2272941A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
NO973900D0 (no) Nitrogenoksyd syntase inhibitorer
DE69941949D1 (de) topische ZUSAMMENSETZUNGEN enthaltend einen alpha 1-adrenergic blocker ZUR BEHANDLUNG VON SCHMERZHAFTEN ZUSTÄNDEN DER ANALREGION
NZ335981A (en) Ketobenzamides as calpain inhibitors
UA49006C2 (uk) Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
ATE271128T1 (de) Inhibitoren der il-6 aktivitaet
HUP0004532A2 (en) Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
EA199900448A1 (ru) Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos
SE9703693D0 (sv) Novel combination
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
IL158559A0 (en) Acne treatment
BR9812371A (pt) Tratamento de distúrbio de conduta
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
NO994640D0 (no) Hostestillende midler
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
NO994330D0 (no) Metode for behandling av en tumor
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
HUP0100066A2 (hu) Egy diol és egy alfa-hidroxisav keverékének alkalmazása hiperkeratózisos bőrbetegségek kezelésére
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ATE245985T1 (de) Verbesserung der opioid-toleranz durch hemmung der induzierbaren stickstoffoxid-synthase zur behandlung von schmerzen
ZA9711468B (en) New use of comt inhibitors
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
AP2001002067A0 (en) New pharmaceutical uses for nos inhibitors.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0966286

Country of ref document: EP

REN Ceased due to non-payment of the annual fee